Inclusion Criteria:  cancer patients ages ≥18 years have received a medication in one of the following categories: platinum-based, vinca alkaloids, bortezomib, eribulin, and/or taxanes have completed their course of chemotherapy three months or more before enrollment have CIN due to receiving neurotoxic chemotherapy for cancer or have pre-existing peripheral neuropathy of another etiology that worsened after chemotherapy have one of the average intensity of pain, or numbness, or tingling on their extremities the previous week due to CIN ≥ 4 on a 11-point numerical scale.  Exclusion Criteria:  use of an investigational agent for pain control concurrently or within the past 30 days use of an implantable drug delivery system, e.g. Medtronic SynchroMed® prior celiac plexus block or other neurolytic pain control treatment other identified causes of painful paresthesia existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy,) allergy to latex (the tapes for the APA include latex).